Sermorelin / GHRP-2 Blend
A research peptide blend combining Sermorelin (a GHRH analogue) and GHRP-2 (a ghrelin receptor agonist), studied for synergistic amplification of growth hormone release through dual pituitary receptor pathway activation.
Overview
Sermorelin binds pituitary GHRH receptors to stimulate GH synthesis and pulsatile secretion, while GHRP-2 activates the growth hormone secretagogue receptor (GHS-R1a), amplifying GH release through a complementary signaling cascade. The rationale for combining these two peptides is rooted in research demonstrating that GHRH and ghrelin-pathway agonists activate distinct intracellular mechanisms that converge on somatotroph GH release, resulting in a response greater than the additive effects of either agent alone.
Mechanism of Action
Sermorelin mimics endogenous GHRH by binding to the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, activating adenylyl cyclase and increasing intracellular cAMP to promote GH gene transcription and secretion. GHRP-2, acting through the GHS-R1a receptor, signals via phospholipase C and protein kinase C pathways. When both receptors are activated simultaneously, the convergent signaling produces a synergistic amplification of GH pulse amplitude. Importantly, this dual mechanism preserves the physiological pulsatile pattern of GH release and maintains negative feedback via IGF-1 and somatostatin, distinguishing it from exogenous GH administration.
Reconstitution Calculator
Research
Synergistic GH Release
The foundational observation supporting GHRH/GHRP combination therapy comes from studies by Bowers et al. (1990), who demonstrated that simultaneous administration of GHRH and GHRP produced GH responses 3-10 times greater than either peptide alone. This synergy has been consistently replicated across multiple species and experimental paradigms.
Metabolic Effects
GHRP-2 has demonstrated effects beyond GH release, including modulation of appetite and energy metabolism through central ghrelin pathways. Muccioli et al. (2002) reviewed the broader metabolic actions of growth hormone secretagogues, including effects on food intake, adiposity, and glucose homeostasis.
GH Axis Stimulation and Aging
Research has explored the use of GHRH analogues combined with GH secretagogues for age-related GH decline. Walker (2006) described sermorelin as a physiologically appropriate approach to managing adult-onset GH insufficiency, noting that it maintains feedback regulation unlike exogenous GH. The addition of GHRP-2 to this approach aims to further amplify the attenuated GH response seen in aging populations.
Combined GHRH + GHRP secretagogue action
The blend pairs sermorelin, a GHRH(1-29) analogue that stimulates pituitary somatotrophs, with GHRP-2 (pralmorelin), a ghrelin-receptor agonist. The two act through complementary receptors and synergize to amplify pulsatile GH release. Sermorelin has approved pediatric GH-deficiency data (Geref), and GHRP-2 is an established GH stimulus and a licensed diagnostic agent in Japan.
- GHRH and GHRP secretagogues act synergistically on GH release
- Sermorelin increased height velocity in GH-deficient children
- GHRP-2 gives robust GH responses and avoids insulin-tolerance-test hypoglycemia
Safety Profile
The safety profiles of both components have been individually characterized. Sermorelin has a well-established safety record from clinical use, with common side effects limited to injection site reactions, flushing, and headache. GHRP-2 may transiently increase cortisol and prolactin levels at higher doses. The combination preserves physiological GH pulsatility and negative feedback mechanisms, which reduces the risk of GH excess compared to exogenous GH administration. Long-term safety data for the specific blend in humans remain limited to individual component studies.
Pharmacokinetic Profile
Sermorelin / GHRP-2 Blend — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Research Indications
Growth Hormone Axis (component peptides)
Sermorelin (GHRH 1-29) and GHRP-2 (pralmorelin) are established GH stimulation agents; GHRP-2 avoids the hypoglycemia risk of the insulin tolerance test.
Sermorelin was approved as a secretagogue to increase height velocity in children (Geref); the blend combines a GHRH analogue with a ghrelin-receptor secretagogue.
Combined GHRH + GHRP secretagogue approach studied to raise endogenous GH pulsatility; clinical benefit not established for anti-aging use.
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
Interactions
Peptide Interactions
This blend combines Sermorelin, a well-characterized growth hormone releasing hormone (GHRH) analogue corresponding to the first 29 amino acids of endogenous GHRH, with GHRP-2, a synthetic hexapeptide ghrelin receptor agonist.
What to Expect
What to Expect
Rapid onset expected; half-life of Sermorelin: ~10-20 min; GHRP-2: ~1-2 hours indicates fast-acting pharmacokinetics
Due to short half-life (Sermorelin: ~10-20 min; GHRP-2: ~1-2 hours), effects are expected per-dose; consistent daily administration maintains...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
Caution
- Injection site reactions reported
Frequently Asked Questions
References (11)
- [4]Donato et al — Growth hormone-releasing hormone/growth hormone secretagogue combination therapy: an updated review Endocrine (2023)
- [5]Sinha et al — Revisiting the role of growth hormone secretagogues in age-related sarcopenia Aging Cell (2023)
- [6]Sigalos & Pastuszak — The role of growth hormone secretagogue receptor signaling in neuroendocrine physiology and metabolic regulation Best Practice & Research Clinical Endocrinology & Metabolism (2022)
- [1]Bowers CY et al On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone Endocrinology (1990)
- [2]Walker RF Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging (2006)
- [3]Muccioli G et al Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity Eur J Pharmacol (2002)
- [7]Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males Translational Andrology and Urology (2020)
→ Describes the Sigalos combined GHS regimen — GHRP-2/GHRP-6/sermorelin dosed at 100 mcg thrice daily subcutaneously — significantly raising IGF-1 in hypogonadal men.
- [8]Prakash A, Goa KL Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs (1999)
→ Establishes sermorelin (GHRH analog) as well tolerated by subcutaneous injection, with facial flushing/injection-site reactions as the main adverse events.
- [9]Geref International Study Group Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy Journal of Clinical Endocrinology & Metabolism (1996)
→ Sermorelin (GHRH 1-29) 30 mcg/kg/day increased mean height velocity from 4.1 to 8.0 cm/yr in GH-deficient children.
- [10]et al. Robust growth hormone responses to GH-releasing peptide 2 in adolescents Clinical Endocrinology (2024)
→ GHRP-2 (pralmorelin) elicited strong, reproducible GH release, supporting its use as a GH secretagogue/diagnostic stimulus.
- [11]Veldhuis JD, et al. Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine growth hormone secretion Journal of Clinical Endocrinology & Metabolism (2010)
→ GHRP-2 and GHRH-type secretagogues drive GH secretion with effects modulated by sex steroids and adiposity.
Sermorelin
Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue consisting of the first 29 amino acids of the 44-amino acid native GHRH sequence. It retains fu
Sermorelin / GHRP-6 Blend
This blend combines Sermorelin, the biologically active N-terminal 29-amino-acid fragment of growth hormone releasing hormone (GHRH), with GHRP-6, a synthetic h